厄洛替尼辅助全脑放疗治疗肺癌脑转移疗效分析

Clinical Analysis on Efficacy of Erlotinib as Adjuvant to the Whole Brain Radiotherapy for Brain Metastasis of Lung Cancer

目的 探讨厄洛替尼辅助全脑放疗治疗肺癌脑转移的临床疗效.方法 回顾性分析2011年9月至2012年11月保定市第二医院收治的18例肺癌脑转移患者的临床资料,采用厄洛替尼辅助全脑放疗治疗的方法,全脑放疗30 Gy/10Fx,同时口服厄洛替尼150 mg/d,放疗结束后2个月评价疗效、生存时间及不良反应.结果 厄洛替尼辅助全脑放疗对肺癌脑转移的总有效率为66.6％,临床获益率为100％;肿瘤进展时间（TTP）为3～15个月,中位TPP为7个月,总生存期为5～18个月,中位生存期为9个月;主要的不良反应为脱发、腹泻和乏力等.结论 厄洛替尼辅助全脑放疗治疗肺癌脑转移疗效确切,不良反应较小,患者能够耐受,且延长患者生存周期,有积极的临床意义.

Objective To investigate the efficacy of erlotinib as adjuvant to the whole brain radiotherapy for brain metastasis of lung cancer.Methods Retrospectively analyzed the clinical reports of 18 cases of brain metastases of lung cancer admitted in Baoding Second City Hospital from Sep.2011 to Nov.2012 in,and treated with erlotinib as adjuvant to the whole brain radiotherapy under the radiotherapy of whole brain 30 Gy/10Fx and oral erlotinib 150 mg/d.Evaluated the curative effect,survival time and adverse reaction 2months after radiotherapy.Results The total efficiency of erlotinib as adjuvant to the whole brain radiotherapy on lung cancer with brain metastasis was 66.6 %,and the clinical benefit rate was 100 %.The tumor progression period （TPP） was 3-15 months,the median TPP was 7 months,the overall smvival period was 5-18 months,the median survival period was 9 months.The main side effects were alopecia,diarrhea and fatigue,etc.Conclusion Using erlotinib as adjuvant to the whole brain radiotherapy for brain metastasis of lung cancer shows definite curative effect,has less adverse effect,and is well tolerated to the patient,and can prolong the survival period of the patient,therefore,has positive clinical significance.